NCT05671432View on ClinicalTrials.gov

The Study of CM326 in Moderate-to-severe Atopic Dermatitis

PHASE2UnknownINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2024

Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
BIOLOGICAL

CM326

CM326 injection

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

Peking University People's hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY